Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ROS study.

被引：0
|
作者：
Garcia-Alfonso, Pilar
Munoz Martin, Andres J.
Jimenez-Castro, Jeronimo
Jimenez-Fonseca, Paula
Pericay, Carles
Longo, Federico
Reyna, Carmen
Argiles, Guillem
Gonzalez Astorga, Beatriz
Jose Gomez-Reina, Maria
Ruiz Casado, Ana
Rodriguez-Salas, Nuria
Lopez-Lopez, Rafael
Carmona Bayonas, Alberto
Conde-Herrero, Veronica
Aranda, Enrique
机构：
[1] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[2] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[3] Hosp Univ Virgen Rocio, Seville, Spain
[4] Hosp Univ Cent Asturias, Oviedo, Spain
[5] Hosp Sabadell, Corp Sanitaria Parc Tauli, Sabadell, Spain
[6] Inst Ramon & Cajal Invest Sanitaria IRICYS, Hosp Univ Ramon & Cajal, CIBERONC, Madrid, Spain
[7] Hosp Univ Reg & Virgen Victoria, Malaga, Spain
[8] Vall Hebron Univ Hosp & Inst Oncol VHIO, TTD Grp, CIBERONC, Barcelona, Spain
[9] Hosp Univ San Cecilio, Granada, Spain
[10] Hosp Univ Puerta Mar, Cadiz, Spain
[11] Hosp Univ Puerta Hierro, Dept Med Oncol, Madrid, Spain
[12] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
[13] Univ Clin Hosp, Dept Med Oncol, Madrid, Spain
[14] Univ Clin Hosp, Translat Med Oncol Grp, Madrid, Spain
[15] Univ Clin Hosp, Hlth Res Inst IDIS, Madrid, Spain
[16] Univ Santiago Compostela, Sch Med, CIBERONC, Santiago De Compostela, Spain
[17] Hosp Gen Univ Morales Meseguer, Murcia, Spain
[18] Hosp Univ Virgen Ias Nieves, Dept Med Oncol, Granada, Spain
[19] Univ Cordoba, Reina Sofia Hosp, IMIBIC, Inst Salud Carlos III,CIBERONC, Cordoba, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e15556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15556
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
    Garcia-Alfonso, Pilar
    Munoz, Andres
    Jimenez-Castro, Jeronimo
    Jimenez-Fonseca, Paula
    Pericay, Carles
    Longo-Munoz, Federico
    Reyna-Fortes, Carmen
    Argiles-Martinez, Guillem
    Gonzalez-Astorga, Beatriz
    Jose Gomez-Reina, Maria
    Ruiz-Casado, Ana
    Rodriguez-Salas, Nuria
    Lopez-Lopez, Rafael
    Carmona-Bayonas, Alberto
    Conde-Herrero, Veronica
    Aranda, Enrique
    CANCERS, 2021, 13 (18)
  • [2] Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
    Prager, Gerald W.
    Taieb, Julien
    Fakih, Marwan
    Ciardiello, Fortunato
    Van Cutsem, Eric
    Elez, Elena
    Cruz, Felipe M.
    Wyrwicz, Lucjan
    Stroyakovskiy, Daniil
    Papai, Zsuzsanna
    Poureau, Pierre-Guillaume
    Liposits, Gabor
    Cremolini, Chiara
    Bondarenko, Igor
    Modest, Dominik P.
    Benhadji, Karim A.
    Amellal, Nadia
    Leger, Catherine
    Vidot, Loick
    Tabernero, Josep
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (18): : 1657 - 1667
  • [3] Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer patients: An AGEO prospective "real life" study.
    Coutzac, Clelia
    Trouilloud, Isabelle
    Artru, Pascal
    Henriques, Julie
    Masson, Therese
    De La Fouchardiere, Christelle
    Doat, Solene
    Bouche, Olivier
    Coriat, Romain
    Saint, Angelique
    Moulin, Valerie
    Vernerey, Dewi
    Tougeron, David
    Taieb, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: A retrospective study
    Li, Rongrong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Liu, Zhen-yang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer
    Tasseau, Clara
    Gallois, Claire
    BULLETIN DU CANCER, 2024, 111 (12) : 1087 - 1088
  • [6] Real-world experience of trifluridine/tipiracil in patients with metastatic colorectal cancer: A multicenter United Kingdom study.
    Stavraka, Chara
    Pouptsis, Athanasios
    Kabuubi, Paul
    Angelis, Vasileios
    Synowiec, Alicja
    Baxter, Mark
    Barrie, Ainsley
    Costa, Amparo Andres
    Nizam, Alia
    De Naurois, Julien
    Mikropoulos, Christos
    Hill, Mark
    Graham, Janet Shirley
    Harris, Victoria
    Bridgewater, John A.
    Ross, Paul J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study
    Li, Rong-Rong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Fruehling, Petter
    Liu, Zhen-Yang
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 612 - 629
  • [8] Prognostic factors in patients receiving trifluridine/tipiracil for refractory metastatic colorectal cancer in the real-life setting: The ROS study
    Garcia-Alfonso, P.
    Reina Zoilo, J.
    Mata Velasco, E.
    Llanos, M.
    Illan Varella, A.
    Safont Aguilera, M.
    Delgado Urena, M.
    Castanon, C.
    Pimentel, P.
    Alonso Orduna, V.
    Mendez, J.
    Rivera Herrero, F.
    Siso, I.
    Rodriguez-Pascual, J.
    Gravalos Castro, C.
    Afonso, R.
    Fernandez Ranada, I.
    Grandez, R.
    Moreno, M.
    Munoz, A. Lopez
    Garcia-Paredes, B.
    Aranda, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S113 - S113
  • [9] Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer
    Celeste B. Burness
    Sean T. Duggan
    Drugs, 2016, 76 : 1393 - 1402
  • [10] Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer
    Burness, Celeste B.
    Duggan, Sean T.
    DRUGS, 2016, 76 (14) : 1393 - 1402
12345